Alcami’s St. Louis Facility Issued European Medicines Agency Certification

News
Article

The company’s center of excellence for advanced analytical testing passed GMP inspection from the European Medicines Agency.

On April 29, 2019, Alcami announced that its St. Louis, MO, center of excellence for advanced analytical testing was issued a certificate of compliance by the European Medicines Agency (EMA) on April 23, 2019 following the facility’s recent successful GMP inspection.

The certification confirms the site is compliant with GMP laboratory storage and testing practices and enables the laboratory to process more commercial products for the European Union (EU). In September 2017, Alcami opened its center of excellence in St. Louis’s Cortex Innovation Community, a 200-acre innovation hub and technology district. The facility provides analytical testing services for manufacturers’ new drug entities, generics, animal health products, APIs, raw materials, in-process goods, medicated consumer health products, chemicals, and biologics. In May 2018, the site was honored by the Missouri House of Representatives and St. Louis Mayor Lyda Krewson with a resolution and letter of commendation recognizing the company’s operational excellence and accomplishments.

Source: Alcami

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes